Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Gigacloud Technology Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Gigacloud Technology Inc trades at $52.01 (market cap $1.84B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.1× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GCT | |
|---|---|---|
Market Cap | $29.60B | $1.84B |
Sector | Health | Technology |
52-Week High | $491.22 | $53.25 |
52-Week Low | $205.48 | $25.44 |
Enterprise Value | $27.56B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
GigaCloud Technology (GCT) trades at $51.66, up 0.02% on the day, with a bullish technical outlook supported by moving averages and strong support at $50. The company reported Q2 2026 EPS of $1.16, beating estimates, and maintains a 10.65% net income margin. Revenue growth is projected to rise from $1.29B in 2025 to $1.5B in 2026, with consistent profitability.
The stock presents a compelling opportunity with attractive valuations (P/E 12.25, P/S 1.3) and robust fundamentals, though overbought RSI levels near 84 suggest near-term consolidation risk. Analyst consensus is bullish with 67% buy ratings, but investors should monitor execution risks in European expansion and furniture market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
